Luveris is a drug owned by Emd Serono Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 16, 2015. Details of Luveris's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5767251 | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof |
Jun, 2015
(9 years ago) |
Expired
|
FDA has granted several exclusivities to Luveris. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Luveris, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Luveris.
Exclusivity Information
Luveris holds 1 exclusivities. All of its exclusivities have expired in 2011. Details of Luveris's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Oct 08, 2011 |
US patents provide insights into the exclusivity only within the United States, but Luveris is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Luveris's family patents as well as insights into ongoing legal events on those patents.
Luveris's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Luveris's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 16, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Luveris Generics:
There are no approved generic versions for Luveris as of now.
About Luveris
Luveris is a drug owned by Emd Serono Inc. Luveris uses Lutropin Alfa as an active ingredient. Luveris was launched by Emd Serono in 2004.
Approval Date:
Luveris was approved by FDA for market use on 08 October, 2004.
Active Ingredient:
Luveris uses Lutropin Alfa as the active ingredient. Check out other Drugs and Companies using Lutropin Alfa ingredient
Dosage:
Luveris is available in injectable form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 75 IU/VIAL | INJECTABLE | Discontinued | SUBCUTANEOUS |